|drugClass=[[antiglaucoma]], [[prostaglandin]] and [[ophthalmologic]] agent
|drugClass=[[antiglaucoma]], [[prostaglandin]] and [[ophthalmologic]] agent
|indicationType=treatment
|indicationType=treatment
|indication=for the lowering of [[intraocular pressure]] in patients with [[open-angle glaucoma]] or [[ocular hypertension]]
|indication=for lowering of [[intraocular pressure]] in patients with [[open-angle glaucoma]] or [[ocular hypertension]]
|adverseReactions=increased hair growth of eyelash, abnormal vision, burning sensation in eye, disorder of eyelid, disorder of lacrimal system, dry eyes, hyperemia of surface of eye and itching of eye
|adverseReactions=increased hair growth of eyelash, [[abnormal vision]], burning sensation in eye, [[Eyelid disease|disorder of eyelid]], [[Lacrimal apparatus disease|disorder of lacrimal system]], [[xerostomia|dry eyes]], [[hyperemia]] of surface of eye and itching of eye
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Rescula (unoprostone isopropyl ophthalmic solution) 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The recommended dosage is one drop in the affected eye(s) twice daily.
Rescula may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If two drugs are used, they should be administered at least five (5) minutes apart.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Unoprostone in adult patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Unoprostone in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Unoprostone in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Unoprostone in pediatric patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Unoprostone in pediatric patients.
Contraindications
Rescula is contraindicated in patients with hypersensitivity to unoprostone isopropyl or any other ingredient in this product.
Warnings
Description
Precautions
Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Unoprostone in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Unoprostone in the drug label.